After uniQure (QURE) announced they have achieved alignment with the FDA on key elements of an accelerated approval pathway for AMT-130, Stifel said this “looks like a best-case scenario,” noting that the company can use an external control and leverage data from the ongoing Phase 1/2 study and can use cUHDRS as the endpoint. This is “a big win for the stock in the backdrop of low expectations that an accelerated path could actually materialize,” says the analyst, who looks forward to more color as uniQure engages the FDA throughout the first half of 2025. Stifel has a Buy rating on uniQure shares, which are up $7.01, or 96%, to $14.30 in pre-market trading.
Pick the best stocks and maximize your portfolio:
- Discover top-rated stocks from highly ranked analysts with Analyst Top Stocks!
- Easily identify outperforming stocks and invest smarter with Top Smart Score Stocks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on QURE:
- Cantor Fitzgerald says ‘aggressively’ buy uniQure, PTC Therapeutics
- uniQure Secures FDA Agreement for AMT-130 Approval
- uniQure announces alignment with FDA on elements of approval path for AMT-130
- uniQure Begins Phase I/IIa Trial for AMT-260 Therapy
- uniQure announces first patient dosed in GenTLE Phase I/IIa trial of AMT-260